--- title: Design and Evaluation of Complex Sequential Analysis Trials description: "Free Webinar: Explore sequential analysis trials in survival analysis. This webinar covers adaptive designs, early stopping, error-spending, and simulations for time-to-event endpoints." image: https://www.statsols.com/hubfs/June%20Webinar%20-%20SignUp.png --- [![nQuery Logo-White](https://www.statsols.com/hs-fs/hubfs/nQuery%20Logo-White.png?width=705&height=175&name=nQuery%20Logo-White.png "nQuery Logo-White")](https://www.statsols.com/) ** ** ![Sample size and power training for use in clinical trials](https://www.statsols.com/hs-fs/hubfs/Master_Images/___PageImages/Software_Training/Sample%20size%20and%20power%20training%20for%20use%20in%20clinical%20trials.jpeg?width=1000&name=Sample%20size%20and%20power%20training%20for%20use%20in%20clinical%20trials.jpeg "Sample size and power training for use in clinical trials") #### Webinar # **Design and Evaluation of Complex Sequential Analysis Trials** ### Sequential Survival Analysis and Simulation for Operating Characteristics ### This webinar has now ended: Watch Now ** #### About the webinar Sequential designs, where trials can stop early based on interim results, are the most widely used type of adaptive design in clinical trials. However, sequential designs still require careful consideration of design choices, particularly in the context of more complex areas such as survival analysis. Simulation can be a vital tool to explore the performance of sequential designs over a wide range of scenarios. In this free webinar, we discuss the choices available for sequential designs, how sequential designs are adapted for complex endpoints such as time-to-event, and how simulation can allow exploration of sequential design’s operating characteristics under a range of scenarios. #### In this free webinar, you will learn about: ** More about the webinar   Sequential designs can greatly reduce the potential cost of a trial by stopping early where evidence is strongly in favour (efficacy) or against (futility) the treatment at an early interim analysis. For example, the accelerated approval of Covid-19 vaccine trials in 2020 were based on sequential design approaches.   A wide variety of methods are available for sequential designs such as error-spending, Haybittle-Peto and Wang-Tsiatis designs with careful consideration between these needed to justify design choices to sponsors and regulators.   These design choices are even more complicated when dealing with complex endpoints such as time-to-event where considerations such as accrual, hazard rates and dropout can have substantial effects on the statistical and practical aspects of study design.    Choosing between different sequential design choices can be difficult but simulation can be used to explore the performance of a sequential design under a wide variety of scenarios including different effect sizes, test statistic choices and stopping boundaries.   These simulations provide context on the expected probability of stopping for efficacy or futility at each interim analysis and the expected overall sample size that will be recruited for a sequential trial under those assumptions.   In this free webinar, we discuss the choices available for sequential designs, how sequential designs are adapted for complex endpoints such as time-to-event and how simulation can allow exploration of sequential design’s operating characteristics under a range of scenarios.   ** #### Duration - 60 minutes **Speaker:** Brian Fox, Research Statistician, nQuery ### Watch Now All info submitted is secure. View our [privacy policy](https://www.statsols.com/privacy-policy). ** About Our Host ****Brian Fox** ![Brian Fox - nQuery Researcher - no bg](https://www.statsols.com/hs-fs/hubfs/Staff_Photos/Headshots/Brian%20Fox%20-%20nQuery%20Researcher%20-%20no%20bg.png?width=150&height=150&name=Brian%20Fox%20-%20nQuery%20Researcher%20-%20no%20bg.png)   #### nQuery Research Statistician **Reducing the risk & cost of clinical trials, for innovative organizations such as:** ![Sanofi-updated-grey](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Sanofi-updated-grey.jpg?width=80&name=Sanofi-updated-grey.jpg "Sanofi-updated-grey") ![worldwide-clinical-trials](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/worldwide-clinical-trials.jpg?width=300&name=worldwide-clinical-trials.jpg "worldwide-clinical-trials") ![Covance-G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Covance-G_Logo.jpg?width=354&name=Covance-G_Logo.jpg "Covance-G_Logo") ![quintiles_logo_2017_grey](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/quintiles_logo_2017_grey.jpg?width=300&name=quintiles_logo_2017_grey.jpg "quintiles_logo_2017_grey") ![FDA_G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/FDA_G_Logo.jpg?width=60&name=FDA_G_Logo.jpg "FDA_G_Logo") ![AstellasG_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/AstellasG_Logo.jpg?width=291&name=AstellasG_Logo.jpg "AstellasG_Logo") ![celgene_logo_download](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/celgene_logo_download.jpg?width=91&name=celgene_logo_download.jpg "celgene_logo_download") ![Boehringer_Ingelheim_Logo-png-updated](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Boehringer_Ingelheim_Logo-png-updated.jpg?width=300&name=Boehringer_Ingelheim_Logo-png-updated.jpg "Boehringer_Ingelheim_Logo-png-updated") ![PRA_Health_Sciences](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/PRA_Health_Sciences.jpg?width=68&name=PRA_Health_Sciences.jpg "PRA_Health_Sciences") ![Astrazeneca logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Astrazeneca%20logo.png?width=322&name=Astrazeneca%20logo.png "Astrazeneca logo") ![Amgen_G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Amgen_G_Logo.jpg?width=350&name=Amgen_G_Logo.jpg "Amgen_G_Logo") ![Novartis_G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Novartis_G_Logo.jpg?width=508&name=Novartis_G_Logo.jpg "Novartis_G_Logo") ![abbvie-logo-updated_tmp15240](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/abbvie-logo-updated_tmp15240.jpg?width=365&name=abbvie-logo-updated_tmp15240.jpg "abbvie-logo-updated_tmp15240") ![Merck_GLogo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Merck_GLogo.jpg?width=310&name=Merck_GLogo.jpg "Merck_GLogo") ![Biogen-updated-logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Biogen-updated-logo.jpg?width=258&name=Biogen-updated-logo.jpg "Biogen-updated-logo") ![Ipsen-logo-only](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Ipsen-logo-only.jpg?width=300&name=Ipsen-logo-only.jpg "Ipsen-logo-only") ![Eli_Lilly_and_Company-G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Eli_Lilly_and_Company-G_Logo.jpg?width=120&name=Eli_Lilly_and_Company-G_Logo.jpg "Eli_Lilly_and_Company-G_Logo") ###### Is there someone in your network that would be interested in our webinar? Share this page by clicking below. [![Share on linkedin](https://7528302.fs1.hubspotusercontent-na1.net/hub/7528302/hubfs/raw_assets/public/mV0_d-web-default-modules_hubspot/img/linkedin-color.png?width=24&name=linkedin-color.png) ](http://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fdesign-and-evaluation-of-complex-sequential-analysis-trials%3Futm_medium%3Dsocial%26utm_source%3Dlinkedin) [![Share on twitter](https://7528304.fs1.hubspotusercontent-na1.net/hub/7528304/hubfs/raw_assets/public/mV0_d-web-default-modules_hubspot/img/twitter-color.png?width=24&name=twitter-color.png) ](https://twitter.com/intent/tweet?original_referer=https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fdesign-and-evaluation-of-complex-sequential-analysis-trials%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&url=https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fdesign-and-evaluation-of-complex-sequential-analysis-trials%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&source=tweetbutton&text=) [![Share on email](https://7528311.fs1.hubspotusercontent-na1.net/hub/7528311/hubfs/raw_assets/public/mV0_d-web-default-modules_hubspot/img/email-color.png?width=24&name=email-color.png) ](mailto:?subject=Check%20out%20https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fdesign-and-evaluation-of-complex-sequential-analysis-trials%3Futm_medium%3Dsocial%26utm_source%3Demail%20&body=Check%20out%20https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fdesign-and-evaluation-of-complex-sequential-analysis-trials%3Futm_medium%3Dsocial%26utm_source%3Demail)